Literature DB >> 14627987

PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase.

Cynthia M Simbulan-Rosenthal1, Dean S Rosenthal, RuiBai Luo, Raed Samara, Luis A Espinoza, Paul O Hassa, Michael O Hottiger, Mark E Smulson.   

Abstract

The transcription factor E2F-1 is implicated in the activation of S-phase genes as well as induction of apoptosis, and is regulated by interactions with Rb and by cell cycle-dependent alterations in E2F-1 abundance. We earlier demonstrated a pivotal role for poly(ADP-ribose) polymerase-1 (PARP-1) in the regulation of E2F-1 expression and promoter activity during S-phase re-entry when quiescent cells re-enter the cell cycle. We now investigate the putative mechanism(s) by which PARP-1 may upregulate E2F-1 promoter activity during S-phase re-entry. DNase-1 footprint assays with purified PARP-1 showed that PARP-1 did not directly bind the E2F-1 promoter in a sequence-specific manner. In contrast to p53, a positive acceptor in poly(ADP-ribosyl)ation reactions, E2F-1 was not poly(ADP-ribosyl)ated by wild-type PARP-1 in vitro, indicating that PARP-1 does not exert a dual effect on E2F-1 transcriptional activation. Protein-binding reactions and coimmunoprecipitation experiments with purified PARP-1 and E2F-1, however, revealed that PARP-1 binds to E2F-1 in vitro. More significantly, physical association of PARP-1 and E2F-1 in vivo also occurred in wild-type fibroblasts 5 h after re-entry into S phase, coincident with the increase in E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes cyclin A and c-Myc. Mapping of the interaction domains revealed that full-length PARP-1 as well as PARP-1 mutants lacking either the catalytic active site or the DNA-binding domain equally bind E2F-1, whereas a PARP-1 mutant lacking the automodification domain does not, suggesting that the protein interaction site is located in this central domain. Finally, gel shift analysis with end-blocked E2F-1 promoter sequence probes verified that the binding of PARP-1 to E2F-1 enhances binding to the E2F-1 promoter, indicating that PARP-1 acts as a positive cofactor of E2F-1-mediated transcription.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627987     DOI: 10.1038/sj.onc.1206897

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

1.  Regulation of poly(ADP-ribose) polymerase-1-dependent gene expression through promoter-directed recruitment of a nuclear NAD+ synthase.

Authors:  Tong Zhang; Jhoanna G Berrocal; Jie Yao; Michelle E DuMond; Raga Krishnakumar; Donald D Ruhl; Keun Woo Ryu; Matthew J Gamble; W Lee Kraus
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

Review 2.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

3.  Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1.

Authors:  K I Amiri; H C Ha; M E Smulson; A Richmond
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

4.  Interaction between PARP-1 and ATR in mouse fibroblasts is blocked by PARP inhibition.

Authors:  Padmini S Kedar; Donna F Stefanick; Julie K Horton; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2008-08-22

5.  Catalytic-Independent Functions of PARP-1 Determine Sox2 Pioneer Activity at Intractable Genomic Loci.

Authors:  Ziying Liu; W Lee Kraus
Journal:  Mol Cell       Date:  2017-02-16       Impact factor: 17.970

Review 6.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

Review 7.  Role of PARP-1 in prostate cancer.

Authors:  Dhanraj Deshmukh; Yun Qiu
Journal:  Am J Clin Exp Urol       Date:  2015-04-25

8.  Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Authors:  Wei Zhang; Bo Liu; Wenhui Wu; Likun Li; Bradley M Broom; Spyridon P Basourakos; Dimitrios Korentzelos; Yang Luan; Jianxiang Wang; Guang Yang; Sanghee Park; Abul Kalam Azad; Xuhong Cao; Jeri Kim; Paul G Corn; Christopher J Logothetis; Ana M Aparicio; Arul M Chinnaiyan; Nora Navone; Patricia Troncoso; Timothy C Thompson
Journal:  Clin Cancer Res       Date:  2017-11-14       Impact factor: 12.531

9.  Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.

Authors:  Xiang Zhao; Dan Li; Dandan Huang; Huajie Song; Hong Mei; Erhu Fang; Xiaojing Wang; Feng Yang; Liduan Zheng; Kai Huang; Qiangsong Tong
Journal:  Mol Ther       Date:  2017-12-22       Impact factor: 11.454

10.  Interaction of Sindbis virus non-structural protein 3 with poly(ADP-ribose) polymerase 1 in neuronal cells.

Authors:  Eunhye Park; Diane E Griffin
Journal:  J Gen Virol       Date:  2009-06-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.